Currently Funded Research - National Multiple Sclerosis Society

Skip to navigation Skip to content

Currently Funded Research

Share

Master Page Does Not Exist

Currently Funded

BloodCenter of Wisconsin

Bonnie Dittel, Ph.D.
Term: 7/1/12-6/30/15
Funding: $450,431
“Regulation of EAE by CD86 expressed within the CNS”Investigating how an immune system signaling molecule suppresses MS-like disease for clues to new treatments to stop MS disease activity.

 

Recently Funded

BloodCenter of Wisconsin

Bonnie Dittel, Ph.D.
Term: 10/1/2010-9/30/2013
Funding: $440,724
“Elucidating the role of cannabinoid receptor 2 in immune regulation during EAE” Looking at how cannabis-related molecules interact with and affect the immune system and their potential for turning off immune attacks.

University of Wisconsin-Madison

Colleen Hayes, Ph.D.
Term: 10/1/2010-9/30/2013
Funding: $585,146
“Vitamin D and estrogen synergy in the control of EAE”Exploring how vitamin D and the sex hormone estrogen may interact to control MS-like immune attacks and its implications for MS.

Colleen Hayes, Ph.D.
Term: 10/1/2009-9/30/2012
Funding: $485,469
“Calcitriol synthesis and IL-10-dependent function in the central nervous system” How vitamin D and vitamin D-derived hormone calcitriol may be used to prevent and treat an MS-like disease in mice for clues to its role in people with MS.

Julie Olson, Ph.D.
Term: 6/1/11-11/30/12
Funding: $44,000
“The role of NHE-1 on microglia during demyelinating disease” Investigating a molecule called “NHE-1” that may increase the immune attack in MS, and how inhibiting NHE-1 may reduce the activation of microglia (cells within the brain and spinal cord that participate in the immune attack in MS.

Aaron Field, M.D., Ph.D.
Term: 7/1/2010-6/30/2012
Funding: $586,436 CCSVI Grant
“Study of CCSVI in MS using quantitative time-resolved 3D MRV” Understanding the role of CCSVI (vein blockage) in MS and identifying optimal methods for screening for the condition.

John Fleming, M.D.
Term: 4/1/2005-3/31/2012
Funding: $567,110
“Helminth-induced immunomodulation therapy (HINT) in relapsing-remitting MS” A novel, pilot clinical trial testing whether ingestion of worm eggs has the potential to alter the immune attack in MS.
Master Page Does Not Exist
Master Page Does Not Exist

Share


Chapter Home Local Research
Master Page Does Not Exist
Master Page Does Not Exist